ACTA1 and pulmonary arterial hypertension: Taken together, these reports could potentially point to a hypothesis that elevated ActA and ActB contribute to the disease progression of PAH, partly by competitive binding to BMPRII thereby further reducing the availability of BMPRII for BMP signalling and exacerbating BMPRII loss.